Induced Pluripotent Stem Cells

Publication date

2020-09

Authors

van Mil, AlainORCID 0000-0001-9906-5047ISNI 0000000388487943
Neef, Klaus
Balk, Geerthe Margriet
Buikema, Jan Willem
Sluijter, Joost P.G.ORCID 0000-0003-2088-9102ISNI 0000000392195257
Doevendans, Pieter A.ISNI 0000000110574516

Editors

Baars, Hubert F
Doevendans, Pieter A. F. M.
Houweling, Arjan C.
van Tintelen, J. Peter

Advisors

Supervisors

Document Type

Part of book

Collections

License

Abstract

Progress in understanding and treatment of numerous human diseases has been hampered by the lack of representative human in vitro models, especially for diseases in which the affected cell types are difficult to obtain, such as heart diseases. Over the past decade, the use of disease affected cell types derived from induced pluripotent stem (iPS) cells has developed into a unique and powerful method to study the pathophysiological mechanisms of human cardiac disease and drive the development of novel targeted therapies. In this chapter, an overview is provided of the iPS-derived cardiomyocyte (iPS-CM) models for inherited cardiac disease that have been studied so far. In addition to the key findings of these individual studies and the progress that has been made since the first iPS-CM disease model, limitations and important methodological considerations are discussed. The current advances in iPS-CM disease modeling and the challenges yet to overcome show that this field holds great promise, but is still in its infancy.

Keywords

Cardiac differentiation, Disease modeling, Induced pluripotent stem cells, Inherited cardiac disease, Pluripotent stem cell-derived cardiomyocytes, Precision medicine, Taverne

Citation

van Mil, A, Neef, K, Balk, G M, Buikema, J W, Sluijter, J P G & Doevendans, PA 2020, Induced Pluripotent Stem Cells. in H F Baars, P A F M Doevendans, A C Houweling & J P van Tintelen (eds), Clinical Cardiogenetics. 3 edn, vol. 2020, Springer International Publishing AG, pp. 439-455. https://doi.org/10.1007/978-3-030-45457-9_26